N/A N=40 Bupropion in the Treatment of Methamphetamine Dependence
Methamphetamine Use Disorder
Primary: Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. — 5.6; 6.0 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=153 Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
Gestational Diabetes Mellitus · Type 2 Diabetes Mellitus · Metabolic Syndrome
Primary: Insulin Secretion-Sensitivity Index (IS-SI) — 418.4; 333 index — p=<0.04
Phase 2 N=75 Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis
Anemia
Primary: Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period — -3.25; 3.5; -2.75 g/L
N/A N=49 A Pilot Clinical Trial of TENA Identifi in the Nursing Home Setting
Urinary Incontinence
Primary: Wet Events Per 24 Hours — 8.11; 5.75; 7.05; 5.45 events per 24 hours
N/A N=38 A Real-Time Ultrasound Guided Approach For Spinal Anesthesia
Patients Aged 55 or Older · BMI More Than 40 kg/m2 · Scoliosis
Primary: Number of Attempts — 1; 1 Attempts — p=0.83
N/A N=7 Family Routines - Healthy Families
Diabetes Mellitus, Type 1
Primary: Effect of Intervention on Evening Glucose Control. — 2 Participants
Phase 2 N=123 Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Colon Adenocarcinoma · Rectal Adenocarcinoma · Stage III Colorectal Cancer AJCC v7
Primary: Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3 — 0.43; 0.26 proportion of patients — p=0.0434
Phase 4 N=54 Investigation of Sugammadex in Outpatient Urological Procedures
Malignant Neoplasms of Urinary Tract · Bladder Cancer
Primary: Muscle Recovery Time — 2; 9.24 minutes
Phase 2 N=91 To Characterize the Performance of the Nasal Dilator Strip in Lowering Nasal Resistance During Sleep, Promoting Nasal Route Breathing and Reducing the Signs and Symptoms of Sleep Disordered Breathing in a Group of Chronic Nocturnal Nasal Congestion Sufferers Who Report Trouble With Their Sleep.
Sleep Disordered Breathing · Congestion, Nasal
Primary: Nasal Resistance in Sleeping State : Nasal Resistance Phase — 2.658; 2.202 Centimeter (cm) H2O/liter/sec — p=0.0147
Phase 2 N=116 Statin Therapy in Acute Influenza
Influenza
Primary: Change in Inflammatory Markers From Time Zero to 72 Hours — 2.4; 3.46; 0.91; 0.57 pg/ml — p=0.611
Phase 3 N=704 Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)
Rhinitis, Allergic
Primary: Change From Baseline in Total Nasal Symptom Score (Assessed by Participant) — 7.9; 7.8; 7.9; 8.0 Score on a scale — p=0.36
Phase 2 N=21 Efficacy of Minoxidil in Children With Williams-Beuren Syndrome
Williams Beuren Syndrome
Primary: Variation of Carotid Intima-media Thickness (IMT) Assessed by Vascular Echography — 0.028; 0.012 mm
N/A N=133 Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000
Aortic Valve Disorder · Aortic Valve Insufficiency · Aortic Valve Stenosis
Primary: Number of Early Adverse Events Divided by Number of Subjects (Expressed as a Percentage) — 2.3; 0.8; 0.0; 0.0 percentage
N/A N=102 Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — NA months
Phase 2 N=4,002 Efficacy and Safety of Dengue Vaccine in Healthy Children
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Number of Symptomatic Virologically-Confirmed Dengue (VCD) Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a Placebo — 45; 32…